Anti-PS Antibody-Cytokine Fusion Protein, IgG (2aG4)-IL2 (CAT#: ACFP-SH006)

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-PS IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the PS as well as the biological activity of IL2. 2aG4-IL2 has great improvement than 2aG4 and IL2 alone. First, the improvement is antigen-specific indicating that 2aG4-IL2 blocks PS-dependent immunosuppressive signals. Second, the improvement is greater with 2aG4-IL2 than with 2aG4 alone, indicating that immunostimulatory cytokine-IL2 contributes to the vaccination. This immunocytokine was designed for treating PS-expressing tumor.